Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

Exclusion Criteria

• •History of significant blood, kidney, endocrine, lung, gastrointestinal, heart, liver, psychiatric, neurologic, or allergic disease
• •Presence or history of deep vein thrombosis or transient ischemic attack
• •History of seizure disorder
• •Presence or history of glaucoma or increased intraocular pressure
• •Allergy to or unable to tolerate tamoxifen, desvenlafaxine, or venlafaxine
• •History of substance abuse within 1 year of study
• •A positive urine drug screen
• •Treatment with an investigational drug within 30 days
• •Consumption of grapefruit or grapefruit related citrus fruits
• •12 lead ECG demonstrating QTc \>450 msec at screening
• •Pregnant or nursing females
• •Use of prescription or nonprescription drugs and dietary supplements
• •History of sensitivity to heparin or heparin induced thrombocytopenia
• •Severe acute or chronic medical or psychiatric condition or laboratory abnormality
• •Use of CYP 2D6 inhibitors and CYP 3A4 inhibitors/inducers